G42 Healthcare, an AI-powered healthcare company, has reportedly inked an LOI (Letter of Intent) with AstraZeneca, a global science-led biopharmaceutical company, with an intention to enlarge their collaboration into the diagnostics and clinical research domains, offering access to improved solutions and treatments for patients in the UAE (United Arab Emirates) and beyond.

The LOI was inked in the presence of the Department of Health (DoH) – Abu Dhabi, the supervisor of the healthcare sector in the emirate of Abu Dhabi.

The deal was inked by Government Affairs, Associate Director Gulf at AstraZeneca, Ghaleb Al Ahdab and Senior Director at G42 Healthcare, Francesco Redivo at the BIO International Convention held at Diego, California.

It was witnessed by Executive Director, Research and Innovation Centre at DoH, Dr. Asma Al Mannaei; Corporate Affairs Director GCC at AstraZeneca, Hicham Mirghani; and Chief Operating Officer, G42 Healthcare, Dr. Fahed Al Marzooqi.

Historically, AstraZeneca and G42 Healthcare inked a Declaration of Collaboration in December 2021. However, this new agreement is a further enlargement of this collaboration for building local research capabilities, conducting RWE/clinical trials in UAE, and localizing the testing of Oncology biomarkers in UAE.

While commenting on the move, Ashish Koshy, CEO of G42 Healthcare, said that the organization values its collaborations, and the firm has faith that this strategic deal with AstraZeneca will provide extraordinary growth to the healthcare ecosystem.

The firm is proud of aligning itself with such organizations and generate new technologies and treatments to strengthen the place of UAE being a global hub for medical tourism, life sciences and innovations.

AstraZeneca’s Corporate Affairs Director GCC, Hicham Mirghani said that the firm is pleased to extend its collaboration with G42 Healthcare to advance the healthcare sector in the country and region.

There is no doubt that innovation is a key to development in healthcare. The firm is keen to look forward to collaboratively exploring new possibilities in clinical diagnostics and research, enabling the firm to build a more patient-centric clinical care in the UAE.

Source Credit - https://www.prnewswire.com/news-releases/g42-healthcare-and-astrazeneca-sign-agreement-to-advance-life-sciences-at-bio-international-convention-301571985.html